# Optimization of imaging mass cytometry, a single-cell spatial proteomics technology, for the study of Alzheimer disease

> **NIH NIH R21** · WASHINGTON UNIVERSITY · 2022 · $433,125

## Abstract

Project Summary
This proposal aims to fill a critical gap in applying high-dimensional single-cell spatial proteomics technology -
imaging mass cytometry (IMC) - to study neurons and glia in the human brains. IMC is an emerging high-plex
technology which combines immunohistochemistry (IHC) staining using metal isotope-labeled antibodies with
laser ablation and mass-spectrometry-based detection to produce high-dimensional images. IMC allows the
detection of 40-100 protein markers simultaneously on tissue sections and enables a variety of distinct cell types
to be analyzed concurrently at a spatially-resolved single-cell resolution. IMC has been applied to cancer,
diabetes, immunology, and infectious disease research, identifying functionally distinct immune cell
subpopulations associated with disease progression, treatment outcomes, and biomarkers for disease prognosis.
As the most common neurodegenerative disease without a disease-modifying treatment, the application of IMC
to Alzheimer disease (AD) could provide novel insights into the disease pathogenesis and targets for the
development of effective therapeutic. This spatially-resolved single-cell resolution proteomic technology is critical
for investigating the impact of AD pathology on different cell types in a spatial context. The extracellular beta-
amyloid (Aβ) plaques and the intracellular neurofibrillary tangles (NFT) are hallmarks of AD pathology. Aβ
plaques have been linked to selective neuronal death in AD and are surrounded by activated astrocytes and
microglia. The burden and location of NFT correlate with neuronal loss, disease severity, and clinical course.
However, the molecular mechanisms underlying AD pathologies in relationship to cellular and gene expression
changes and neurodegeneration in the human brain remain unclear, which significantly hampers the
development of effective treatment strategies. The main challenge of applying IMC to AD research is the lack of
a well-designed, validated high-quality antibody panel suited for the brain tissue. This proposal will fill this gap
by developing a 37-antibody panel for the analysis of snap-frozen human brain tissues using IMC which will
include both the markers to identify all the major cell types in the central nervous system and biomarkers of AD
pathologies. In Aim 1, we will design and optimize the immunodetection conditions for a 37-antibody panel for
use on postmortem human brain tissue sections and apply the technology to the frontal cortex tissues of AD and
matched control cases. In Aim 2, we will develop and optimize a computational pipeline for brain tissue-specific
IMC data analysis. This technology could be used to obtain comprehensive spatial information of brain
microenvironment and cell-cell interactions among the glia and neurons, which will advance our understanding
of how the spatial distribution of Aβ plaques and NFTs affect glial activation and neuronal death. This optimized
methodology will provide the neurosc...

## Key facts

- **NIH application ID:** 10447479
- **Project number:** 1R21AG077643-01
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Jinbin Xu
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $433,125
- **Award type:** 1
- **Project period:** 2022-04-15 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10447479

## Citation

> US National Institutes of Health, RePORTER application 10447479, Optimization of imaging mass cytometry, a single-cell spatial proteomics technology, for the study of Alzheimer disease (1R21AG077643-01). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10447479. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*